NewsBenzingaSCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis SCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis Benzinga 2026.10.22 12:03 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181 Evercore ISI Group Maintains Outperform on Meta Platforms, Raises Price Target to $870 Dow Warns High Interest Rates and Weak Consumer Confidence Are Hurting Housing Demand Evercore ISI Group Maintains Outperform on Knight-Swift, Raises Price Target to $79 Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75 Stock of the Day: Where is the Bottom for AT&T?
Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181
Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75
